Real-world experience of afatinib as first-line therapy for advanced
Afatinib
epidermal growth factor receptor (EGFR)
first-line
non-small cell lung cancer (NSCLC)
real-world
Journal
Translational lung cancer research
ISSN: 2218-6751
Titre abrégé: Transl Lung Cancer Res
Pays: China
ID NLM: 101646875
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
received:
07
07
2021
accepted:
11
11
2021
entrez:
24
1
2022
pubmed:
25
1
2022
medline:
25
1
2022
Statut:
ppublish
Résumé
We investigated the clinical characteristics and treatment outcomes of Korean patients receiving first-line afatinib for advanced epidermal growth factor receptor mutation-positive ( Electronic case reports were retrospectively reviewed from patients across 15 sites in South Korea. Outcome measures included baseline characteristics, overall response rate (ORR), time-to-treatment discontinuation (TTD), and overall survival (OS). Subgroups were: presence/absence of brain metastases at baseline, dose reductions, and baseline Among 422 patients, 39.8% had brain metastases and 59.0%/25.1%/10.0%/5.0% had Del19/L858R/compound/uncommon Afatinib was well tolerated with no new safety signals, and efficacy was encouraging in Korean patients with
Sections du résumé
BACKGROUND
BACKGROUND
We investigated the clinical characteristics and treatment outcomes of Korean patients receiving first-line afatinib for advanced epidermal growth factor receptor mutation-positive (
METHODS
METHODS
Electronic case reports were retrospectively reviewed from patients across 15 sites in South Korea. Outcome measures included baseline characteristics, overall response rate (ORR), time-to-treatment discontinuation (TTD), and overall survival (OS). Subgroups were: presence/absence of brain metastases at baseline, dose reductions, and baseline
RESULTS
RESULTS
Among 422 patients, 39.8% had brain metastases and 59.0%/25.1%/10.0%/5.0% had Del19/L858R/compound/uncommon
CONCLUSIONS
CONCLUSIONS
Afatinib was well tolerated with no new safety signals, and efficacy was encouraging in Korean patients with
Identifiants
pubmed: 35070746
doi: 10.21037/tlcr-21-501
pii: tlcr-10-12-4353
pmc: PMC8743522
doi:
Types de publication
Journal Article
Langues
eng
Pagination
4353-4367Informations de copyright
2021 Translational Lung Cancer Research. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://dx.doi.org/10.21037/tlcr-21-501). YCK reports receiving research grant and honorarium from AstraZeneca, research grant from Boehringer Ingelheim, and honorarium from Roche outside the submitted work. TWJ reports receiving honoraria and grants or funds from BI outside the submitted work. The other authors have no conflicts of interest to declare.
Références
Target Oncol. 2018 Jun;13(3):269-285
pubmed: 29700687
J Thorac Oncol. 2020 May;15(5):803-815
pubmed: 31931137
Cancer Res Treat. 2020 Apr;52(2):351-358
pubmed: 32178488
Ann Oncol. 2016 Nov;27(11):2103-2110
pubmed: 27601237
Ann Oncol. 2014 Feb;25(2):423-8
pubmed: 24478319
Lancet Oncol. 2019 Dec;20(12):1655-1669
pubmed: 31591063
Asia Pac J Clin Oncol. 2018 Mar;14 Suppl 1:7-9
pubmed: 29508940
Cancer Res Treat. 2019 Apr;51(2):502-509
pubmed: 29898592
ESMO Open. 2021 Jun;6(3):100115
pubmed: 33984681
Transl Lung Cancer Res. 2015 Feb;4(1):36-54
pubmed: 25806345
Sci Transl Med. 2017 Nov 15;9(416):
pubmed: 29141884
Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):839-44
pubmed: 16467097
Clin Cancer Res. 2006 Jul 1;12(13):3908-14
pubmed: 16818686
J Clin Oncol. 2017 Apr 20;35(12):1288-1296
pubmed: 28221867
Lung Cancer. 2019 Jan;127:169-171
pubmed: 30477806
Oncotarget. 2015 Nov 17;6(36):38789-803
pubmed: 26515464
Clin Cancer Res. 2015 Dec 1;21(23):5305-13
pubmed: 26206867
Lung Cancer. 2017 Jul;109:137-144
pubmed: 28577943
Lung Cancer. 2019 Jan;127:103-111
pubmed: 30642537
Lancet Oncol. 2016 May;17(5):577-89
pubmed: 27083334
Semin Oncol. 2019 Jun;46(3):271-283
pubmed: 31558282
EMBO Mol Med. 2011 Nov;3(11):623-36
pubmed: 21953712
Ther Adv Med Oncol. 2019 Apr 15;11:1758835919836374
pubmed: 31019567
Clin Cancer Res. 2011 Mar 1;17(5):1169-80
pubmed: 21248300
Mol Cancer Ther. 2013 Feb;12(2):220-9
pubmed: 23371856
BMC Cancer. 2021 Jul 12;21(1):802
pubmed: 34253172
N Engl J Med. 2018 Jan 11;378(2):113-125
pubmed: 29151359
Target Oncol. 2019 Feb;14(1):75-83
pubmed: 30539501
J Clin Oncol. 2013 Sep 20;31(27):3327-34
pubmed: 23816960
Lancet Oncol. 2015 Jul;16(7):830-8
pubmed: 26051236
Lancet Oncol. 2014 Feb;15(2):213-22
pubmed: 24439929
Lung Cancer. 2021 Jan;151:20-24
pubmed: 33279874
Medicine (Baltimore). 2019 Jan;98(1):e13890
pubmed: 30608413
Oncogene. 2008 Aug 7;27(34):4702-11
pubmed: 18408761
N Engl J Med. 2017 Feb 16;376(7):629-640
pubmed: 27959700
J Natl Cancer Inst. 2017 Nov 1;109(11):
pubmed: 29059439
Cancer Res Treat. 2019 Oct;51(4):1400-1410
pubmed: 30913875
Lung Cancer. 2020 Feb;140:71-79
pubmed: 31884129
Cancer Med. 2021 Sep;10(17):5809-5822
pubmed: 34258882
Ann Oncol. 2017 Feb 1;28(2):270-277
pubmed: 28426106
Ther Adv Med Oncol. 2021 May 6;13:17588359211012361
pubmed: 33995597
J Pharmacol Exp Ther. 2012 Nov;343(2):342-50
pubmed: 22888144
Lancet Oncol. 2015 Feb;16(2):141-51
pubmed: 25589191
Future Oncol. 2018 Nov;14(27):2861-2874
pubmed: 30336693
J Thorac Oncol. 2016 Mar;11(3):380-90
pubmed: 26823294
J Cancer Res Clin Oncol. 2019 Jun;145(6):1569-1579
pubmed: 30783814
Lung Cancer. 2019 Apr;130:87-92
pubmed: 30885357
Future Oncol. 2018 May;14(11):1117-1132
pubmed: 29336166
Future Oncol. 2020 Dec;16(34):2799-2808
pubmed: 32854536
Tuberc Respir Dis (Seoul). 2016 Oct;79(4):248-256
pubmed: 27790276